Fatty acid ␤-oxidation occurs in both mitochondria and peroxisomes. Long chain fatty acids are also metabolized by the cytochrome P450 CYP4A -oxidation enzymes to toxic dicarboxylic acids (DCAs) that serve as substrates for peroxisomal ␤-oxidation. Synthetic peroxisome proliferators interact with peroxisome proliferator activated receptor ␣ (PPAR␣) to transcriptionally activate genes that participate in peroxisomal, microsomal, and mitochondrial fatty acid oxidation. Mice lacking PPAR␣ (PPAR␣ ؊/؊ ) fail to respond to the inductive effects of peroxisome proliferators, whereas those lacking fatty acyl-CoA oxidase (AOX ؊/؊ ), the first enzyme of the peroxisomal ␤-oxidation system, exhibit extensive microvesicular steatohepatitis, leading to hepatocellular regeneration and massive peroxisome proliferation, implying sustained activation of PPAR␣ by natural ligands. We now report that mice nullizygous for both PPAR␣ and AOX (PPAR␣ ؊/؊ AOX ؊/؊ ) failed to exhibit spontaneous peroxisome proliferation and induction of PPAR␣-regulated genes by biological ligands unmetabolized in the absence of AOX. In AOX ؊/؊ mice, the hyperactivity of PPAR␣ enhances the severity of steatosis by inducing CYP4A family proteins that generate DCAs and since they are not metabolized in the absence of peroxisomal ␤-oxidation, they damage mitochondria leading to steatosis. Blunting of microvesicular steatosis, which is restricted to few liver cells in periportal regions in PPAR␣ ؊/؊ AOX ؊/؊ mice, suggests a role for PPAR␣-induced genes, especially members of CYP4A family, in determining the severity of steatosis in livers with defective peroxisomal ␤-oxidation. In agematched PPAR␣ ؊/؊ mice, a decrease in constitutive mitochondrial ␤-oxidation with intact constitutive peroxisomal ␤-oxidation system contributes to large droplet fatty change that is restricted to centrilobular hepatocytes. These data define a critical role for both PPAR␣ and AOX in hepatic lipid metabolism and in the pathogenesis of specific fatty liver phenotype.
chain, medium chain, and short chain acyl-CoA dehydrogenases (VLCAD, LCAD, MCAD, and SCAD respectively) (2, 3) . The second, third, and fourth steps in the mitochondrial ␤-oxidation spiral are carried out by a 2-enoyl-CoA hydratase (MH), a 3-hydroxyacyl-CoA dehydrogenase (HADH), and a 3-ketoacyl-CoA thiolase (MTL1) (3) . The MH, HADH, and MTL activities lie within mitochondrial trifunctional protein (TFP) (3) .
Of these two peroxisomal ␤-oxidation systems, the enzymes belonging to the classical group are markedly induced in conjunction with profound proliferation of peroxisomes in the liver of rats and mice by a group of structurally diverse agents designated as peroxisome proliferators (6) . These synthetic peroxisome proliferators exert their pleiotropic effects in liver by activating a nuclear receptor called peroxisome proliferatoractivated receptor ␣ (PPAR␣) (7) . The induction of peroxisome proliferation is associated with transcriptional activation of genes encoding for the peroxisomal ␤-oxidation system and cytochrome P450 CYP 4A isoforms, CYP4A1 and CYP4A3, among others (8 -11) . For this to occur, PPAR␣ heterodimerizes with retinoid X receptor, and this PPAR-retinoid X receptor complex binds to PPAR response element, a region consisting of a degenerate direct repeat of the canonical AGGTCA sequence separated by 1 base pair (DR1), present in the 5Ј-flanking region of target genes (12) . The generation of PPAR␣ Ϫ/Ϫ mice established that this receptor is essential for hepatic peroxisome proliferation and coordinate transcriptional activation of AOX, L-PBE, PTL, CYP4A,1 and CYP4A3 and other genes by structurally diverse synthetic peroxisome proliferators (13) . PPAR␣ Ϫ/Ϫ mice display normal complement of peroxisomes in liver cells, but these mice remain nonresponsive to the inductive influence of synthetic peroxisome proliferators (13) . A mild degree of centrilobular fatty change develops in these mice that is attributed to reduction in the constitutive levels of mitochondrial fatty acid ␤-oxidation, because the constitutive or basal oxidation of VLCFAs by peroxisomal ␤-oxidation system appears unaffected by PPAR␣ deficiency (14) . We investigated the functional implications of disrupting the basal metabolism of VLCFAs by generating mice deficient in AOX, the first enzyme of inducible peroxisomal ␤-oxidation system, and found that AOX Ϫ/Ϫ mice develop severe microvesicular steatohepatitis and spontaneous peroxisome proliferation in liver cells (15, 16) . These results suggested that very long chain and long chain acyl-CoAs and other putative substrates for classical AOX play a role in triggering spontaneous peroxisome proliferation by functioning as PPAR␣ ligands if they remain unmetabolized and in the development of microvesicular hepatic steatosis (16) . The morphological and biochemical changes observed in AOX Ϫ/Ϫ mice suggested a sustained hyperfunction of PPAR␣ because of biological ligands (16) . Although PPAR␣ is essential for the induction of pleiotropic responses by synthetic peroxisome proliferators as evidenced from studies in PPAR␣ Ϫ/Ϫ mice (13), it is uncertain if the spontaneous peroxisome proliferation induced by biological mediators in AOX-deficient mice is effected by PPAR␣ or by some other mechanism.
In the present study, we investigated the potential for in vivo compensatory functions by generating mice deficient in both PPAR␣ and AOX. We report that these double nullizygous mice (PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ ) do not show spontaneous hepatic peroxisome proliferation, implying that PPAR␣ deficiency is not compensated by other transcription factors. Also pertinent is that the microvesicular steatosis was markedly diminished in PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice in comparison to severe steatosis observed in AOX Ϫ/Ϫ mice, suggesting that the presence of PPAR␣ exaggerates steatosis developing in the absence of peroxisomal ␤-oxidation.
EXPERIMENTAL PROCEDURES

Generation of PPAR␣
Ϫ/Ϫ AOX Ϫ/Ϫ Mice-The generation of PPAR␣ nulls and AOX nulls has been described elsewhere (13, 15 (13) , and PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice, 3 to 4 months of age, were used in these studies. They were fed powdered diet with or without ciprofibrate (0.0125% w/w), a peroxisome proliferator, for 2 weeks. For light microscopy, tissues were fixed in 10% neutral buffered formalin and embedded in paraffin. Histological analysis was carried out on 4-m-thick sections stained with hematoxylin and eosin. Frozen sections of liver (5-m thick) were used for Sudan black histochemical staining of lipids. For cytochemical localization of catalase (CTL), tissues were processed and examined as described elsewhere (17) .
Western Blot Analysis and Quantitation of Protein-Protein concentrations were determined by a protein assay kit (Bio-Rad) using bovine serum albumin as standard. Contents of ␤-oxidation enzymes and other proteins in liver were determined by immunoblot analysis of total liver proteins using polyclonal antibodies raised in rabbits against rat palmitoyl-CoA synthetase (PCS), AOX, L-PBE, PTL, D-PBE, carnitine octanoyltransferase (COT), very long-chain acyl-CoA synthetase, carnitine acetyltransferase (CAT), peroxisomal membrane protein (PMP) 70, PMP 26, PMP 22, VLCAD, LCAD, MCAD, and SCAD, electron transfer flavoprotein, MH, HADH, TFP, MTL1, mitochondrial acetoacetyl-CoAspecific thiolase (MTL2), urate oxidase (UOX), and glycolate oxidase as described previously (14, 18) . Antibody against the amino-terminal part of SCPx expressed in Escherichia coli was a gift from Professor Yukio Fujiki.
Northern Hybridization-Total RNA was isolated from liver using Trizol reagent (Life Technologies, Inc.). After glyoxylation, samples were electrophoresed on 0.8% agarose gel, transferred to nylon membrane, and then hybridized at 42°C in 50% formamide hybridization solution using 32 P-labeled cDNA probes CTL, L-PBE, PTL, UOX, CYP4A1, CYP4A3, liver fatty acid-binding protein, and 28 S RNA as described previously (16) . Changes in mRNA levels were estimated by densitometric scanning of autoradiograms. (13) and AOX ϩ/Ϫ mice (15) were cross-bred to generate mice nullizygous for both PPAR␣ and AOX (PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ ) used in this study. Southern analysis of tail tip DNA from double heterozygous (PPAR␣ ϩ/Ϫ AOX ϩ/Ϫ ) mice revealed two bands (8.0 and 13.4 kb) with AOX probe and two bands (6.3 and 7.5 kb) with PPAR␣ probe (Fig. 1) . The genomic DNA from double nullizygous (PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ ) mice yielded a single 13.4-kb band with AOX probe and a single 7.5-kb band with PPAR␣ probe (Fig. 1) . In contrast, the DNA from a wild type mouse showed an 8.0-kb band with AOX probe and a 6.3-kb band with PPAR␣ probe. The livers of mice nullizygous for both PPAR␣ and AOX did not show the presence of AOX mRNA and protein when analyzed, respectively, by northern and Western blotting. Both male and female PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice were fertile and displayed no apparent gross phenotypic changes. These double nullizygous mice were grossly indistinguishable from PPAR␣ Ϫ/Ϫ mice and from wild type mice, whereas growth retardation was common in pre-weaning and young AOX (Fig. 2, A, C, and D) . These cells stained positively for fat when stained with Oil Red O or with Sudan black (Fig. 2E) . Few clusters of inflammatory aggregates, reminiscent of lipogranulomatous lesions found in AOX Ϫ/Ϫ mouse liver (16) , were also found among liver cells with microvesicular fatty change in PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mouse liver (Fig. 2D ). The fatty change was generally restricted to periportal location, and even in this zone, a majority of hepatocytes appeared normal. Very few or no hepatocytes with microvesicular fatty change were present in midzonal and centrilobular regions ( mice displayed extensive microvesicular steatohepatitis, and with age, there was age-progressive hepatocellular regeneration commencing in periportal region and extending toward centrizonal region (Fig. 2 , G and H). PPAR␣ Ϫ/Ϫ mice revealed a normal complement of peroxisome profiles in liver parenchymal cells (Fig. 3A) , and the number of these organelles was not increased when these mice were treated with a peroxisome proliferator (13) . As reported previously, liver cells with microvesicular steatosis contained few peroxisomes, whereas regenerated hepatocytes in mice deficient in AOX showed profound spontaneous peroxisome proliferation (Fig. 3 , B and C), indicating a sustained activation of PPAR␣ because of biological ligands of PPAR␣ that require AOX for inactivation or metabolism (16) . We surveyed for alterations in peroxisome population in livers of PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice to ascertain if natural/biological ligands that are not metabolized in the absence of AOX induce peroxisome proliferation in the absence of PPAR␣ in these animals, possibly by activating a different transcription factor such as PPAR␤. No spontaneous peroxisome proliferation was discerned in liver parenchymal cells of PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice, when sections processed for the cytochemical localization of peroxisomal catalase were examined at the light microscopic level (Fig. 3 , D and E). Periportal liver cells with microvesicular fatty change in these double nullizygous mice contained few peroxisomes (Fig. 3D) ; similar paucity of peroxisomes was also noted in hepatocytes with microvesicular steatosis in AOX Ϫ/Ϫ mice (15) . Liver cells of mice deficient in both PPAR␣ and AOX also failed to respond to synthetic peroxisome proliferators in comparison to wild type mice (Fig. 3F) ). These observations clearly indicate that PPAR␣ is the principal transcription factor responsible for the phenomenon of peroxisome proliferation induced by both natural/biological ligands, as well as synthetic peroxisome proliferators. Fatty Acid-activating Enzymes-VLCAS exhibits specificity toward very long chain fatty acids, whereas PCS catalyzes the activation of long chain fatty acids to the CoA esters (19) . The content of hepatic VLCAS was not much different among AOX Ϫ/Ϫ , PPAR␣ Ϫ/Ϫ , and PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice ( Table I ). The amount of PCS, an enzyme with tripartite (microsomal, mitochondrial, and peroxisomal) distribution (20) , increased ϳ2-fold in wild type mice treated with ciprofibrate (Table I) . The hepatic PCS content in AOX Ϫ/Ϫ mice maintained on control diet was also elevated with no further increase occurring when these mice were treated with ciprofibrate (Table I) . A slight increase in PCS content occurred in the livers of ciprofibrate-treated PPAR␣ Ϫ/Ϫ mice and also in PPAR␣
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mice, suggesting that the increase may represent A and B forms of this enzyme and not the PPAR␣-regulated C-form of PCS (21) . Peroxisomal Proteins- Table I and Fig. 4 depict the relative amounts of peroxisomal proteins in wild type, PPAR␣
, and AOX Ϫ/Ϫ mouse livers. A 20-fold increase in COT content occurred in wild type mice treated with ciprofibrate, similar to that reported previously in rat liver with other peroxisome proliferators (22) . The hepatic COT content in AOX Ϫ/Ϫ mice was 20-fold higher than that of wild type controls; this increase was comparable with that observed in ciprofibrate-treated wild type mice. COT content in PPAR␣ Ϫ/Ϫ mice and in PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice was similar to that present in wild type mice, and these nulls did not respond to ciprofibrate treatment, suggesting that COT gene transcription is regulated by PPAR␣. As expected, a marked increase in the amounts of AOX, L-PBE and PTL, three enzymes of the inducible classical peroxisomal ␤-oxidation system, occurred in the livers of wild type mice treated with a peroxisome proliferator (Table I ; Fig. 4 ). Significant increases in AOX and L-PBE proteins occurred in wild type mice fed ciprofibrate. AOX was not detected in livers of AOX Ϫ/Ϫ and PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice (Table I). L-PBE level was 20-fold higher in AOX Ϫ/Ϫ mice, and the amount of this enzyme did not change following ciprofibrate treatment. Hepatic L-PBE levels in PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ and PPAR␣ Ϫ/Ϫ mice were lower as compared with wild type mice, and no significant increase occurred following ciprofibrate treatment.
In wild type mice, hepatic PTL content increased after the administration of ciprofibrate, and this increase was similar to that seen in AOX Ϫ/Ϫ mice on control diet (Table I) . Two isozymes of PTL (constitutive and inducible) are present in rats, but on SDS-polyacrylamide gel electrophoresis they appear as one band. The products of two PTL genes are synthesized as larger precursors; the amino-terminal pre-piece is then cleaved upon translocation of the enzyme into peroxisomes (23, 24) . Two PTL bands were seen in AOX Ϫ/Ϫ mouse liver but not in any other groups (Fig. 4) . The main band appears to be the mature subunit, and the slower moving band is assumed to be immature PTL (Fig. 4) . When the antibody was absorbed with purified PTL, both bands disappeared, indicating that these two bands specifically represent PTL and that in AOX Ϫ/Ϫ liver cells the proteolytic processing of PTL is not complete, similar to that reported in patients with rhizomelic chondrodysplasia punctata (25) (26) (27) . Whether this processing is defective in cells with microvesicular steatosis or this defect is present in all hepatocytes in AOX Ϫ/Ϫ liver remains unclear.
D-PBE and SCPx are two enzymes participating in the second D-3-hydroxy-specific ␤-oxidation pathway (3, 4) . These enzymes catalyze the conversion of straight chain as well as 2-methyl-branched chain fatty acids and bile acid precursors (3, 5) . A marginal increase in D-PBE occurred in wild type mice treated with ciprofibrate but not in PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ and PPAR␣ Ϫ/Ϫ mice (Fig. 4) . SCPx content was essentially similar among all groups (Table I and Fig. 4) .
We assessed the changes in the levels of three peroxisomal matrix proteins (CTL, UOX, and glycolate oxidase) (28, 29) (Table I) . CTL levels increased marginally (Ͻ2-fold) in wild type mice fed ciprofibrate and in mice with AOX gene disruption. No change in the content of UOX and glycolate oxidase occurred in these animals. PMP 70 level increased ϳ4-fold in wild type mice treated with ciprofibrate and in AOX null mice on control diet, possibly reflecting spontaneous peroxisome proliferation (Table I) .
Mitochondrial Enzymes-Carnitine palmitoyltransferase I catalyzes the transfer of a long chain fatty acyl group from coenzyme A to carnitine. Carnitine palmitoyltransferase II, an enzyme located in the inner mitochondrial membrane, then converts fatty acylcarnitines into CoA esters, which then undergo ␤-oxidation (31, 32) . The expression of carnitine palmitoyltransferase II increased ϳ3-fold in the livers of AOX Ϫ/Ϫ mice on control diet and in ciprofibrate-treated wild type mice Table II Immunoblot analysis for CAT revealed three signal bands (Fig. 5) , and these were confirmed as CAT by competing out the antibodies with pigeon breast muscle CAT (data not shown). CAT content in the livers of AOX Ϫ/Ϫ mice was ϳ10-fold higher than that found in wild type mice, and this increase was comparable with that seen in ciprofibrate-treated wild type mice. No increase in CAT content occurred in the livers of PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ and PPAR␣ Ϫ/Ϫ mice fed ciprofibrate (Table II) . Four acyl-CoA dehydrogenases, namely VLCAD, LCAD, MCAD, and SCAD, participate in mitochondrial fatty acid ␤-oxidation (33, 34) . VLCAD content in wild type mice increased only slightly with ciprofibrate treatment, and its content was also higher in AOX Ϫ/Ϫ mice when compared with wild type mice (Table II and Fig. 5 ). Increases in the quantities of the remaining three classical acyl-CoA dehydrogenases, LCAD, MCAD, and SCAD, also occurred in wild type mice treated with ciprofibrate (Table II, Fig. 5 ). Levels of these three enzymes in AOX Ϫ/Ϫ mice were higher than that in wild type mice, and ciprofibrate did not cause additional increases in AOX Ϫ/Ϫ mice (Table II, Fig. 5 ). In PPAR␣ Ϫ/Ϫ and double nullizygous mice, the levels of these proteins were comparable with that present in wild type mice. No increases in the quantities of these enzymes occurred in these animals following ciprofibrate administration.
The hepatic levels of electron transfer flavoprotein and MH remained essentially the same in all groups. The content of HADH was higher in ciprofibrate-treated wild type mice and in mice with AOX deficiency. The quantity of ␣-and ␤-subunits of TFP (35, 36) increased in AOX Ϫ/Ϫ mouse liver (Table II (Fig. 6) . There was no increase in the levels of these mRNAs in PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ (Fig. 6 ) and PPAR␣ Ϫ/Ϫ (data not shown) mice fed ciprofibrate. A slight decrease in fatty acid-binding protein mRNA occurred in PPAR␣ Ϫ/Ϫ and in double nullizygous mice. No appreciable change in UOX and CTL mRNA levels was discerned among different groups.
DISCUSSION
In animals, fatty acids stored as triacylglycerols and formed from de novo synthesis constitute the main fuel sources. These are metabolized at the intracellular level mostly via the mitochondrial and peroxisomal ␤-oxidation enzyme systems (2, 37, 38) . The substrate spectra of these two fatty acid oxidation systems partly overlap, with oxidation of the major portion of medium and long chain fatty acids occurring in mitochondria and that of the VLCFAs taking place preferentially in peroxisomes (2, 3). LCFAs and VLCFAs are also metabolized by the microsomal CYP4A1 and CYP4A3 fatty acid -oxidases, resulting in the formation of DCAs that are further degraded by peroxisomal ␤-oxidation system (39, 40) . LCFAs constitute the bulk of fatty acids in animals, and their abundance makes them the only significant source of metabolic fuel for mitochondrial ␤-oxidation system (2). Under normal physiologic conditions, mitochondrial ␤-oxidation is the dominant metabolic pathway, whereas the extramitochondrial fatty acid oxidation occurring within peroxisomes and endoplasmic reticulum assumes a minor role (2, 3) . Accordingly, decreased mitochondrial fatty acid ␤-oxidation has been considered one of the major mechanisms underlying the disturbances in lipid metabolism in liver leading to steatosis (41) (42) (43) . Oxidation of fatty acids by mitochondria depends not only upon the ␤-oxidation enzymes and substrate concentration but is also influenced by other factors such as changes in carnitine content and oxidative phosphorylation (41) . The extramitochondrial oxidation (peroxisomal ␤-oxidation and microsomal -oxidation) of LCFAs and VLCFAs, on the other hand, is not constrained by confounding events and remains a reflection of enzyme-substrate availability (2, 3) . In view of some overlap of substrate spectra (especially LCFAs) between mitochondrial and extramitochondrial oxidation pathways (2, 3), delineation of cross-talk between these metabolic systems in the pathogenesis of disturbances of lipid metabolism and fatty liver phenotypes becomes important. Here we have described the generation and initial characterization of a mouse nullizygous for both PPAR␣ and peroxisomal AOX. Comparison of changes in the levels of several proteins involved in mitochondrial and extramitochondrial fatty acid oxidation and profiles of morphologic alterations in livers of mice deficient in AOX Ϫ/Ϫ , PPAR␣ Ϫ/Ϫ , and PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ in this study provided new insights regarding the role of VLCFA metabolism by peroxisomal ␤-oxidation system vis à vis AOX, the role of PPAR␣ in the acuity of steatosis developing in mice deficient in AOX possibly by inducing CYP4A family enzymes, and the dominant role of constitutive mitochondrial oxidation in the blunting of hepatic steatosis in mice deficient in both PPAR␣ and AOX.
The striking findings in mice nullizygous for both PPAR␣ and AOX were the absence of spontaneous peroxisome proliferation, the marked attenuation of the extent of microvesicular steatosis in liver, and the lack of liver cell proliferation, in contradistinction to that observed in AOX-deficient genotype. As described previously, mice deficient in AOX develop extensive microvesicular steatosis in liver, which is followed by hepatocellular regeneration and profound spontaneous peroxisome proliferation presumably because of sustained activation of PPAR␣ by natural ligands that require AOX for metabolism (16) . In these mice, several genes encoding for peroxisomal, mitochondrial, and microsomal proteins such as L-PBE, PTL, MCAD CYP4A1, and CYP4A3 were up-regulated in liver, suggestive of spontaneous sustained PPAR␣ hyperactivity analogous to that seen in the livers of wild type mice exposed to synthetic peroxisome proliferators (16) . We proposed that LCFAs and VLCFAs or their acyl-CoAs and other putative substrates for AOX serve as natural ligands for PPAR␣ and that AOX is indispensable for the physiological regulation of PPAR␣ by keeping the natural ligands in check (16) . Mice deficient in L-PBE (the second enzyme of this classical peroxisomal ␤-oxidation spiral) do not show hepatic steatosis and spontaneous peroxisome proliferation, further confirming that disruption of ␤-oxidation pathway distal to AOX does not affect the metabolism of natural ligands of PPAR␣ (18) . In PPAR␣ Ϫ/ ϪAOX Ϫ/Ϫ mice, we did not observe spontaneous peroxisome proliferation and found no evidence of overexpression of L-PBE, PTL, CYP4A1, CYP4A3, and other genes unlike that found in the livers of mice deficient in AOX (16) . These observations establish unequivocally that PPAR␣ is responsible for spontaneous peroxisome proliferation induced by natural ligands whose metabolism depends on intact AOX activity (16, 18) . Thus, in double nulls, even though natural ligands are expected to be abundant, the absence of PPAR␣ in these mice abrogates spontaneous peroxisome proliferation, indicating that PPAR␣ is not redundant. The loss of this receptor is not compensated by the other PPAR isotypes, namely PPAR␤ and PPAR␥, or by any other factor(s). Accordingly, natural ligands that require AOX for inactivation as well as synthetic peroxisome proliferators exert their pleiotropic effects by activating PPAR␣. This assumption is further supported by the finding that administration of synthetic peroxisome proliferators to AOX Ϫ/Ϫ mice does not result in an additive induction of proteins in liver, suggesting that natural ligands essentially saturate PPAR␣ in AOX Ϫ/Ϫ livers. If natural ligands were acting on a different transcription factor, such as PPAR␤, to induce spontaneous peroxisome proliferation in AOX Ϫ/Ϫ mice, then administration of a peroxisome proliferator that activates PPAR␣ would result in additional increases in the gene activity.
Young AOX Ϫ/Ϫ mice develop extensive microvesicular steatosis affecting the entire liver lobule, but little is known about the molecular mechanisms of hepatic steatosis and its disappearance with the emergence of regenerated hepatocytes in these mutant mice (15, 16) . The results obtained from PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice, in which fatty liver is remarkably blunted with few scattered cells in periportal regions, strongly suggest that the absence of peroxisomal ␤-oxidation of fatty acids imposes a major toxic burden on hepatocytes provided the PPAR␣ function is intact. LCFAs and VLCFAs and their CoA esters or some other AOX substrate not metabolized because of AOX deficiency may be particularly toxic to hepatocyte plasma or mitochondrial membranes, leading to injury and dysfunction (44) . The functional PPAR␣ leads to the transcriptional activation of CYP4A1 and CYP4A3 genes in AOX Ϫ/Ϫ mouse liver by natural PPAR␣ ligands, such as VLCFAs or their acyl-CoA esters that remain unmetabolized in the absence of AOX (16) . The increased levels of CYP4A1 and CYP4A3 in AOX Ϫ/Ϫ mouse liver will then metabolize LCFAs into DCAs that are toxic to mitochondria, as they can uncouple oxidative phosphorylation (45) . The absence of PPAR␣ in PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice most likely limits the generation of toxic DCAs by this extramitochondrial fatty acid oxidation pathway and minimizes mitochondrial damage, thereby reducing steatosis. Basal levels of DCAs produced in these double nulls cannot be further degraded because of AOX deficiency and possibly account for the presence of steatotic cells scattered in periportal regions (Fig.  2, C-E) . This limited microvesicular steatosis in double nullizygous mice is most likely because of constitutive or basal expression of CYP4A1 and CYP4A3 and lack of inducibility of these enzymes in the absence of PPAR␣. An intriguing possibility is that in AOX Ϫ/Ϫ mice, unmetabolized PPAR␣ ligands also activate PPAR␣ to induce hepatocellular proliferation and that dividing cells may be more susceptible to steatosis in AOX deficiency. However, once the cell division is complete, regenerated hepatocytes generally exhibit resistance to toxic insults, and this reasoning is consistent with the absence of steatosis in older AOX Ϫ/Ϫ mice (16) and also in chronic alcoholic liver disease (46) . Absence of hepatocellular regeneration in PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ mice because of deficiency of PPAR␣ can contribute to the blunting of microvesicular steatosis and the appearance of periportal fatty phenotype in these animals. In mice deficient in PPAR␣, hepatic steatosis was mild with large droplet fatty change involving few hepatocytes in the centrilobular regions (Fig. 2) . We propose that in PPAR␣ Ϫ/Ϫ genotype, constitutive levels of expression of extramitochondrial fatty acid oxidation systems (peroxisomal ␤-oxidation and microsomal -oxidation) are able to metabolize LCFAs and Ϫ/Ϫ mice also on control diet. Lanes 9 and 10 represent mice nullizygous for both PPAR␣ and AOX on control diet. Lanes 11 and 12 represent PPAR␣ Ϫ/Ϫ AOX Ϫ/Ϫ (DKO) mice on ciprofibrate-containing diet. Twenty g of total RNA was electrophoresed on a 0.8% agarose gel, blotted onto a nylon membrane, and probed with different random-primed 32 P-labeled cDNA probes as shown. The 28 S RNA is for loading control. FABP, fatty acid-binding protein.
VLCFAs and thus prevent or minimize their toxic manifestations. The mild degree of fatty change is attributed to slight but sustained reduction in constitutive mitochondrial ␤-oxidation in PPAR␣ null genotype (14) . As these PPAR␣ Ϫ/Ϫ mice get older, they become obese, and centrilobular steatosis becomes somewhat more pronounced (47) .
The studies with these genetically altered mice underscore the importance of PPAR␣ and peroxisomal ␤-oxidation, in particular the critical role of AOX in hepatic lipid metabolism (Fig.  7) . As proposed in Fig. 7 , PPAR␣ deficiency alone can downregulate mitochondrial ␤-oxidation, but the overall short term consequences appear insignificant as long as the constitutive extramitochondrial fatty acid oxidation is maintained. On the other hand, chronic PPAR␣ deficiency vis à vis sustained reduction in basal mitochondrial ␤-oxidation leads to obesity and a mild to moderate degree of centrilobular fatty change in liver (47) . In contrast, inhibition of peroxisomal ␤-oxidation at the level of AOX in animals with intact PPAR␣ exerts severe abnormalities of lipid metabolism similar to that observed in children with Reye's syndrome (45) . If PPAR␣ is also deficient along with AOX, there is a marked attenuation of this disturbance in lipid metabolism as evidenced in mice nullizygous for both PPAR␣ and AOX. We attribute this to the ability of PPAR␣ to up-regulate CYP4A family genes and the resultant generation of toxic DCAs in AOX Ϫ/Ϫ mice and not in mice deficient in both PPAR and AOX. Accordingly, it would be important to assess the relative levels of PPAR␣ and of peroxisomal ␤-oxidation in human liver and their role in lipid homeostasis (48, 49) . Alterations in PPAR␣ and AOX can affect lipid homeostasis, and changes in the extramitochondrial lipid metabolism may be as important, if not more important than the mitochondrial oxidation in the pathogenesis of fatty liver. In PPAR␣ Ϫ/Ϫ mice, constitutive mitochondrial ␤-oxidation is reduced and leads to slow progression of large droplet centrilobular steatosis in liver. The constitutive extramitochondrial fatty acid metabolism (peroxisomal and CYP4A metabolism of LCFAs and VLCFAs) is not adversely unaffected in the absence of PPAR␣. In AOX Ϫ/Ϫ mice, the sustained hyperactivity of PPAR␣ because of ligands that are not metabolized because of AOX deficiency results in overexpression of CYP4A enzymes, and the LCFAs and VLCFAs not metabolized by peroxisomal ␤-oxidation because of lack of AOX are converted to DCAs by CYP4A -oxidation. Extensive microvesicular steatosis is considered a reflection DCA induced inhibition of mitochondrial ␤-oxidation. In mice nullizygous for both PPAR␣ and AOX, the absence of PPAR␣ and lack of CYP4A induction resulted in the blunting of microvesicular steatosis.
